Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
06 08 2022
Historique:
received: 21 05 2021
accepted: 22 07 2022
entrez: 6 8 2022
pubmed: 7 8 2022
medline: 10 8 2022
Statut: epublish

Résumé

The tumour stroma, and in particular the extracellular matrix (ECM), is a salient feature of solid tumours that plays a crucial role in shaping their progression. Many desmoplastic tumours including breast cancer involve the significant accumulation of type I collagen. However, recently it has become clear that the precise distribution and organisation of matrix molecules such as collagen I is equally as important in the tumour as their abundance. Cancer-associated fibroblasts (CAFs) coexist within breast cancer tissues and play both pro- and anti-tumourigenic roles through remodelling the ECM. Here, using temporal proteomic profiling of decellularized tumours, we interrogate the evolving matrisome during breast cancer progression. We identify 4 key matrisomal clusters, and pinpoint collagen type XII as a critical component that regulates collagen type I organisation. Through combining our proteomics with single-cell transcriptomics, and genetic manipulation models, we show how CAF-secreted collagen XII alters collagen I organisation to create a pro-invasive microenvironment supporting metastatic dissemination. Finally, we show in patient cohorts that collagen XII may represent an indicator of breast cancer patients at high risk of metastatic relapse.

Identifiants

pubmed: 35933466
doi: 10.1038/s41467-022-32255-7
pii: 10.1038/s41467-022-32255-7
pmc: PMC9357007
doi:

Substances chimiques

COL12A1 protein, human 0
Collagen Type I 0
Collagen Type XII 0
Collagen 9007-34-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4587

Informations de copyright

© 2022. The Author(s).

Références

Biophys J. 2005 Feb;88(2):1377-86
pubmed: 15533922
Cancers (Basel). 2019 Jun 01;11(6):
pubmed: 31159419
Cell. 2009 Nov 25;139(5):891-906
pubmed: 19931152
Semin Cancer Biol. 2005 Oct;15(5):329-41
pubmed: 15970443
J Cell Biol. 1997 Feb 10;136(3):729-43
pubmed: 9024701
Elife. 2021 Jun 09;10:
pubmed: 34106045
Trends Cancer. 2016 Jun;2(6):279-282
pubmed: 28741525
Breast Cancer Res. 2016 Jan 08;18(1):5
pubmed: 26747277
Dev Cell. 2019 May 6;49(3):332-346
pubmed: 31063753
Science. 2001 Nov 23;294(5547):1708-12
pubmed: 11721053
Mol Cell Proteomics. 2012 Apr;11(4):M111.014647
pubmed: 22159717
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Breast Cancer Res. 2015 Jun 04;17:79
pubmed: 26040322
Oncogene. 2005 Feb 3;24(6):1104-10
pubmed: 15690056
Sci Rep. 2017 Dec 4;7(1):16887
pubmed: 29203823
Cancer Res. 2020 Apr 1;80(7):1461-1474
pubmed: 32029550
Breast Cancer Res. 2008;10(1):201
pubmed: 18226174
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Cancer Rep (Hoboken). 2020 Feb;3(1):e1209
pubmed: 32671954
Nat Commun. 2020 Sep 9;11(1):4520
pubmed: 32908154
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Methods Cell Biol. 2020;156:109-160
pubmed: 32222216
Sci Adv. 2021 Oct;7(40):eabh0363
pubmed: 34586840
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634
pubmed: 28652369
Oncogene. 2021 Jan;40(3):475-491
pubmed: 33235291
J Clin Invest. 2020 Nov 2;130(11):5721-5737
pubmed: 32721948
Cancer Cell. 2021 Apr 12;39(4):548-565.e6
pubmed: 33667385
Am J Pathol. 2008 Sep;173(3):844-55
pubmed: 18688028
Cell Rep. 2021 Apr 13;35(2):108945
pubmed: 33852842
Elife. 2014 Mar 11;3:e01308
pubmed: 24618895
Cell. 2018 Feb 8;172(4):841-856.e16
pubmed: 29395328
Trends Biochem Sci. 1991 May;16(5):191-4
pubmed: 1882421
Nat Rev Mol Cell Biol. 2014 Dec;15(12):771-85
pubmed: 25370693
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
BMC Med. 2006 Dec 26;4(1):38
pubmed: 17190588
Oncotarget. 2012 Mar;3(3):267-85
pubmed: 22408128
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Mol Med Rep. 2019 Oct;20(4):3103-3112
pubmed: 31432110
Hum Mol Genet. 2014 May 1;23(9):2353-63
pubmed: 24334769
J Exp Med. 2021 May 3;218(5):
pubmed: 33822843
Mol Biol Cell. 2002 Oct;13(10):3546-59
pubmed: 12388756
Nat Med. 2017 Jul;23(7):890-898
pubmed: 28604702
J Clin Invest. 2021 Jun 1;131(11):
pubmed: 33905375
Cell Rep. 2021 Sep 14;36(11):109689
pubmed: 34525350
Nat Commun. 2021 Apr 20;12(1):2328
pubmed: 33879793
Dis Model Mech. 2011 Mar;4(2):165-78
pubmed: 21324931
Int J Biochem Cell Biol. 2014 Aug;53:51-4
pubmed: 24801612
Cancer Res. 2009 Aug 1;69(15):6339-46
pubmed: 19584278
Nat Protoc. 2012 Mar 08;7(4):654-69
pubmed: 22402635
Cell. 2020 Apr 16;181(2):486-486.e1
pubmed: 32302576
Nat Cell Biol. 2013 Jun;15(6):637-46
pubmed: 23708000
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
J Cell Biol. 2007 Dec 17;179(6):1311-23
pubmed: 18086923
Cell Rep. 2020 Jun 2;31(9):107701
pubmed: 32492417
Matrix Biol. 2021 Jan;95:52-67
pubmed: 33096204
Trends Cancer. 2019 Nov;5(11):724-741
pubmed: 31735290
Nat Commun. 2018 Jul 24;9(1):2897
pubmed: 30042390
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Matrix Biol. 2020 Dec;94:57-76
pubmed: 32890632
Am J Pathol. 2022 Feb;192(2):308-319
pubmed: 34774848
Nature. 2021 Nov;599(7886):673-678
pubmed: 34732895
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Curr Protoc Cell Biol. 2016 Jun 01;71:10.9.1-10.9.34
pubmed: 27245425
J Histochem Cytochem. 2014 Oct;62(10):751-8
pubmed: 25023614
Histopathology. 2016 Jul;69(1):25-34
pubmed: 26588661
Nat Commun. 2019 Aug 12;10(1):3637
pubmed: 31406163
Breast Cancer Res. 2016 May 03;18(1):45
pubmed: 27142210
Biomaterials. 2017 Jun;128:147-159
pubmed: 28327460
J Proteome Res. 2017 Aug 4;16(8):3083-3091
pubmed: 28675934
Sci Transl Med. 2017 Apr 5;9(384):
pubmed: 28381539
Am J Pathol. 2011 Mar;178(3):1221-32
pubmed: 21356373
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Cancer Res. 2020 Apr 1;80(7):1475-1485
pubmed: 32019869
Curr Opin Cell Biol. 2016 Oct;42:80-93
pubmed: 27214794
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
N Engl J Med. 2002 Sep 19;347(12):886-94
pubmed: 12239257
Nat Cell Biol. 2021 Jul;23(7):758-770
pubmed: 34226698
J Biol Chem. 2006 Sep 15;281(37):27461-70
pubmed: 16861231
Mol Cell Proteomics. 2017 Dec;16(12):2296-2309
pubmed: 29070702
Matrix Biol Plus. 2020 Jan 20;6-7:100021
pubmed: 33543019
Nat Mater. 2021 Apr;20(4):548-559
pubmed: 33257795
Mol Cell Biol. 1992 Mar;12(3):954-61
pubmed: 1312220
Exp Cell Res. 2004 Aug 1;298(1):305-15
pubmed: 15242785
J Vis Exp. 2011 Oct 13;(56):e3089
pubmed: 22025017
EMBO J. 2020 Oct 1;39(19):e104063
pubmed: 32790115
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19609-19618
pubmed: 31484774
Matrix Biol. 2020 Dec;94:77-94
pubmed: 32950601
Cancer Cell. 2019 Jan 14;35(1):64-80.e7
pubmed: 30612941
Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):138-145
pubmed: 29141852
Front Oncol. 2018 Sep 05;8:337
pubmed: 30234012
Nat Rev Cancer. 2021 Apr;21(4):217-238
pubmed: 33589810
Nat Protoc. 2019 Jan;14(1):68-85
pubmed: 30464214
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Cancer Med. 2020 Jul;9(13):4743-4755
pubmed: 32356618
J Cell Biochem. 2002;87(2):208-20
pubmed: 12244573
Histochem J. 1979 Jul;11(4):447-55
pubmed: 91593
J Biophotonics. 2010 Jan;3(1-2):34-43
pubmed: 19771581
Cancer Res. 2015 Mar 15;75(6):963-73
pubmed: 25600648

Auteurs

Michael Papanicolaou (M)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Amelia L Parker (AL)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Michelle Yam (M)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Elysse C Filipe (EC)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Sunny Z Wu (SZ)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Jessica L Chitty (JL)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Kaitlin Wyllie (K)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Emmi Tran (E)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Ellie Mok (E)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Audrey Nadalini (A)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Joanna N Skhinas (JN)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Morghan C Lucas (MC)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.

David Herrmann (D)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Max Nobis (M)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Brooke A Pereira (BA)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Andrew M K Law (AMK)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.

Lesley Castillo (L)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.

Kendelle J Murphy (KJ)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Anaiis Zaratzian (A)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.

Jordan F Hastings (JF)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.

David R Croucher (DR)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Elgene Lim (E)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Brian G Oliver (BG)

School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
Woolcock Institute of Medical Research, Respiratory Cellular and Molecular Biology, The University of Sydney, Sydney, NSW, Australia.

Fatima Valdes Mora (FV)

Cancer Epigenetic Biology and Therapeutics, Personalised Medicine, Children's Cancer Institute, Sydney, NSW, 2031, Australia.
School of Women's and Children's Health, Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia.

Benjamin L Parker (BL)

Metabolic Systems Biology Laboratory, Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, NSW, Australia.

David Gallego-Ortega (D)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
School of Biomedical Engineering, Faculty of Engineering and Information Technology, University of Technology Sydney, Sydney, NSW, Australia.

Alexander Swarbrick (A)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Sandra O'Toole (S)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.

Paul Timpson (P)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia. p.timpson@garvan.org.au.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. p.timpson@garvan.org.au.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia. p.timpson@garvan.org.au.

Thomas R Cox (TR)

The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia. t.cox@garvan.org.au.
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. t.cox@garvan.org.au.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia. t.cox@garvan.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH